DOI: http://dx.doi.org/10.22516/25007440.115

Efectos adversos a largo plazo de los inhibidores de la bomba de protones. Perspectiva desde la medicina basada en la evidencia

Jaime Cardona-Ospina, Diego Alejandro Medina-Morales, Alfonso Rodríguez-Morales, Jorge Machado-Alba

Resumen


Los inhibidores de la bomba de protones (IBP) son los supresores de la secreción gástrica más efectivos y se encuentran entre los medicamentos de mayor formulación y venta en Estados Unidos; en algunos casos son prescritos sin indicación justificada. En años recientes, el reporte de reacciones adversas importantes relacio- nadas con su uso ha suscitado preocupación. Sin embargo, la calidad de la evidencia no ha sido concluyente y, en algunos casos, la magnitud del riesgo no es de importancia clínica. El objetivo de esta revisión es pre- sentar la evidencia disponible frente a los eventos adversos de mayor importancia relacionados con los IBP. 


Palabras clave


Inhibidores de la bomba de protones; efectos colaterales y reacciones adversas relacionadas con medicamentos; medicina basada en evidencia; farmacovigilancia (fuente: DeCS)

Texto completo:

PDF PDF (English)

Referencias


Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs. 2012; 72(4):437-45.

Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007; 83(975): 66-8.

Ramirez E, Lei SH, Borobia AM, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol 2010; 5(4): 288-97.

Chubineh S, Birk J. Proton Pump Inhibitors: The Good, the Bad, and the Unwanted. South Med J. 2012; 105(11):613-8. 5. Gilard M, Arnaud B, Le Gal G, et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006; 4(11):2508-9.

Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J

Med. 2010; 363(20):1909-17.

Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH,

Doros G, et al. Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. Am J Med. 2016.

Huang B, Huang Y, Li Y, et al Adverse cardiovascular effects of concomitant use of proton pump inhibitors and clopidogrel in patients with coronary artery disease: a systematic review and meta-analysis. Arch Med Res. 2012; 43(3):212-24.

Kwok CS, Jeevanantham V, Dawn B, et al. No consistent evidence of differential cardiovascular risk amongst proton- pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol. 2013; 167(3):965-74.

Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011; 106(7):1209-18.

Arj A, Razavi Zade M, Yavari M, et al. Proton pump inhibi- tors use and change in bone mineral density. Int J Rheum Dis. 2016.

Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of frac- tures with acid-suppressing medication. Bone. 2011; 48(4):768-76.

Williams C, McColl KE. Review article: proton pump inhi- bitors and bacterial overgrowth. Aliment Pharmacol Ther. 2006; 23(1):3-10.

Proton pump inhibitors: bacterial pneumonia. Prescrire Int. 2012; 21(130):210-2.

Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of com- munity-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012; 5(3):337-44

Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta- analysis. CMAJ. 2011; 183(3):310-9.

Lin PC, Chang CH, Hsu PI, et al. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis. Crit Care Med 2010; 38(4):1197-205.

Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infec- tion. Aliment Pharmacol Ther 2011; 34(11-12):1269-81.

Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107(7):1011-9.

Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One.2012; 7(12):e50836.

Gill SK, O’Brien L, Einarson TR, et al. The safety of pro- ton pump inhibitors in pregnancy: a meta-analysis. Am J Gastroenterol. 2009; 104(6):1541-5.

Hak E, Mulder B, Schuiling-Veninga CC, et al. Use of Acid- Suppressive Drugs in Pregnancy and the Risk of Childhood Asthma: Bidirectional Crossover Study using the General Practice Research Database. Drug Saf. 2013; 36(11):1097-104.

Klepser DG, Collier DS, Cochran GL. Proton pump inhi- bitors and acute kidney injury: a nested case-control study. BMC Nephrol. 2013; 14(1):150.

den Elzen WP, Groeneveld Y, de Ruijter W, et al. Long- term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther. 2008; 27(6):491-7.

Rozgony NR, Fang C, Kuczmarski MF, et al. Vitamin B(12)

deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyano- cobalamin nasal spray be beneficial? J Nutr Elder. 2010; 29(1):87-99.

Damiao CP, Rodrigues AO, Pinheiro MF, et al. Prevalence of vitamin B12 deficiency in type 2 diabetic patients using metformin: a cross-sectional study. Sao Paulo Med J. 2016.

Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006; 355(17):1834-6.

Mackay JD, Bladon PT. Hypomagnesaemia due to proton- pump inhibitor therapy: a clinical case series. QJM. 2010; 103(6):387-95.

Hoorn EJ, van der Hoek J, de Man RA, et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis. 2010; 56(1):112-6.

Florentin M, Elisaf MS. Proton pump inhibitor-induced hypomagnesemia: A new challenge. World J Nephrol. 2012; 1(6):151-4.

U.S. Food and Drug Administration. FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs) http://www.fda.gov/drugs/drugsafety/ucm245011. htm2011 [cited 2014 02/09].

Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol. 2013; 27(3):443-54

Yang YX, Metz DC. Safety of proton pump inhibitor expo- sure. Gastroenterology. 2010; 139(4):1115-27.

Eslami L, Nasseri-Moghaddam S. Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions? Arch Iran Med. 2013; 16(8):449-58.

Robertson DJ, Larsson H, Friis S, et al. Proton pump inhi- bitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology. 2007; 133(3):755-60.

Trikudanathan G, Israel J, Cappa J, et al. Association bet- ween proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients – a systematic review and meta-analysis. Int J Clin Pract. 2011; 65(6):674-8.

Goel GA, Deshpande A, Lopez R, et al. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol. 2012; 10(4):422-7.

Kwon JH, Koh SJ, Kim W, et al. Mortality associated with pro- ton pump

inhibitors in cirrhotic patients with spontaneous bac- terial peritonitis. J Gastroenterol Hepatol. 2014; 29(4):775-81.

Bajaj JS, Ratliff SM, Heuman DM, et al. Proton pump inhi- bitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther. 2012; 36(9):866-74.

Gouraud A, Vochelle V, Descotes J, et al. Proton pump inhibitor-induced neutropenia: possible cross-reactivity between omeprazole and pantoprazole. Clin Drug Investig. 2010; 30(8):559-63.


Métricas de artículo

Cargando métricas ...

Metrics powered by PLOS ALM

Enlaces refback

  • No hay ningún enlace refback.


Copyright (c) 2017 Revista Colombiana de Gastroenterología

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

ISSN versión impresa 0120-9957

ISSN versión en línea 2500-7440

  Licencia de Creative Commons
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.